RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000019.xml
Fortschr Neurol Psychiatr 2012; 80(3): 167-179
DOI: 10.1055/s-0031-1299095
DOI: 10.1055/s-0031-1299095
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York
Botulinumtoxin in der klinischen Neurologie
Botulinum Toxin in Clinical NeurologyWeitere Informationen
Publikationsverlauf
Publikationsdatum:
09. März 2012 (online)
Lernziele
Der vorliegende Artikel gibt einen aktuellen Überblick über die bestehenden Indikationen mit erwiesener Wirksamkeit der Behandlung mit Botulinum-Neurotoxin Typ A (BoNT-A) sowie über Empfehlungen zur praktischen Anwendung von BoNT-A. Der Leser verfügt nach der Lektüre über Kenntnisse zur Indikationsstellung, Durchführung und Evaluation der Behandlung.
Literatur
- 1 Jahn R. Neuroscience. A neuronal receptor for botulinum toxin. Science. 2006; 312 540-541
- 2 Kessler K R, Benecke R. The EBD test – a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord. 1997; 12 95-99
- 3 Muller K, Mix E, Adib Saberi F et al. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm. 2009; 116 579-585
- 4 Yablon S A, Brashear A, Gordon M F et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007; 29 683-690
- 5 Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol. 2006; 13 (Suppl 1) 11-15
- 6 Borodic G. Therapeutic botulinum toxin. Lancet. 1994; 344 1370
- 7 Gracies J M, Lugassy M, Weisz D J et al. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009; 90 9-16
- 8 Barnes M, Schnitzler A, Medeiros L et al. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies – a randomized parallel-group study. Acta Neurol Scand. 2010; 122 295-302
- 9 Francisco G E, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil. 2002; 8 355-363
- 10 Gracies J M, Lugassy M, Weisz D J et al. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009; 90 9-16
- 11 Molloy F M, Shill H A, Kaelin-Lang A et al. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology. 2002; 58 805-807
- 12 Chin T Y, Graham H K. Botulinum toxin A in the management of upper limb spasticity in cerebral palsy. Hand Clin. 2003; 19 591-600
- 13 Yang E J, Rha D W, Yoo J K et al. Accuracy of manual needle placement for gastrocnemius muscle in children with cerebral palsy checked against ultrasonography. Arch Phys Med Rehabil. 2009; 90 741-744
- 14 Berweck S, Schroeder A S, Fietzek U M et al. Sonographyguided injection of botulinum toxin in children with cerebral palsy. Lancet. 2004; 363 249-250
- 15 Berweck S, Wissel J. Sonographic imaging for guiding botulinum toxin injections in limb muscles. Adv Clin Neurosci Rehab. 2004; 4 28-31
- 16 Berweck S, Heinen F. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord. 2004; 19 162-167
- 17 Fietzek U M, Schroeder A S, Wissel J et al. Split-screen video demonstration of sonography-guided muscle identification and injection of botulinum toxin. Mov Disord. 2010; 25 2225-2228
- 18 Ashford S, Turner-Stokes L. Goal attainment for spasticity management using botulinum toxin. Physiother Res Int. 2006; 11 24-34
- 19 Wissel J, Ward A B, Erztgaard P et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009; 41 13-25
- 20 Wissel J, auf dem Brinke M, Hecht M et al. Botulinum-Neurotoxin in der Behandlung der Spastizität im Erwachsenenalter. Nervenarzt. 2011; 82 481-495
- 21 Kanovský P, Slawek J, Denes Z et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009; 32 259-65
- 22 Kaňovský P, Slawek J, Denes Z et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011; 43 486-492
- 23 Elovic E P, Brashear A, Kaelin D et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008; 89 799-806
- 24 Bakheit A M, Fedorova N V, Skoromets A et al. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry. 2004; 75 1558-1561
- 25 Mohammadi B, Balouch S A, Dengler R et al. Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients. Neurol Res. 2010; 32 309-313
- 26 Gordon M F, Brashear A, Elovic E et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology. 2004; 63 1971-1973
- 27 Lagalla G, Danni M, Reiter F et al. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil. 2000; 79 377-384
- 28 Sutherland D H, Kaufman K R, Wyatt M P et al. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture. 1999; 10 1-9
- 29 Ubhi T, Bhakta B B, Ives H L et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child. 2000; 83 481-487
- 30 Baker R, Jasinski M, Maciag-Tymecka I et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol. 2002; 44 666-675
- 31 Koman L A, Mooney 3 rd J F, Smith B P et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebocontrolled trial. BOTOX Study Group. J Pediatr Orthop. 2000; 20 108-115
- 32 Wissel J, Heinen F, Schenkel A et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of „high-dose“ versus „lowdose“ treatment. Neuropediatrics. 1999; 30 120-124
- 33 Polak F, Morton R, Ward C et al. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol. 2002; 44 551-555
- 34 Heinen F, Desloovere K, Schroeder A S et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010; 14 45-66
- 35 Hägglund G, Andersson S, Düppe H et al. Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care program and new techniques to reduce spasticity. J Pediatr Orthop B. 2005; 14 269-273
- 36 Naumann M, Albanese A, Heinen F et al. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol. 2006; 13 (Suppl 4) 35-40
- 37 Schramm A, Ndayisaba J, auf dem Brinke M et al. Therapie der Spastik mit onabotulinumtoxin A – erweiterte praktische Erfahrungen in 10 spezialisierten deutschen Zentren. Aktuelle Neurologie. 2011; 38 99-110
- 38 Simpson D M, Blitzer A, Brashear A et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008; 70 1699-1706
- 39 Poewe W, Deuschl G, Nebe A et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998; 64 13-17
- 40 Brans J W, Lindeboom R, Snoek J W et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996; 46 1066-1072
- 41 Benecke R, Jost W H, Kanovsky P et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005; 64 1949-1951
- 42 Brashear A, Hogan P, Wooten-Watts M et al. Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia. Advances in Therapy. 2005; 22 49-55
- 43 Haussermann P, Marczoch S, Klinger C et al. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Movement Disorders. 2004; 19 303-308
- 44 Truong D, Brodsky M, Lew M et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010; 16 316-323
- 45 Mohammadi B, Buhr N, Bigalke H et al. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res. 2009; 31 463-466
- 46 Reichel G, Stenner A, Jahn A. Zur Phänomenologie der zervikalen Dystonien. Fortschr Neurol Psychiatr. 2009; 77 272-277
- 47 Roggenkämper P, Jost W H, Bihari K et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006; 113 303-312
- 48 Jankovic J, Comella C, Hanschmann A et al. Efficacy and safety of incobotulinumtoxin A in the treatment of blepharospasm – A randomized trial. Mov Disord. 2011; 26 1521-1528
- 49 Wabbels B, Reichel G, Fulford-Smith A et al. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm. 2011; 118 233-239
- 50 Mejia N I, Vuong K D, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005; 20 592-597
- 51 Hsiung G Y, Das S K, Ranawaya R et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord. 2002; 17 1288-1293
- 52 Bentivoglio A R, Fasano A, Ialongo T et al. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res. 2009; 15 224-231
- 53 Truong D, Comella C, Fernandez H H et al. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008; 14 407-414
- 54 Albanese A, Bentivoglio A R, Colosimo C et al. Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients. J Neurol Neurosurg Psych. 1996; 60 693-694
- 55 Jankovic J, Schwartz K, Clemence W et al. A randomized, double-blind, placebocontrolled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996; 11 250-256
- 56 Brin M F, Lyons K E, Doucette J et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001; 56 1523-1528
- 57 Naumann M, So Y, Argoff C E et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008; 70 1707-1714
- 58 Naumann M, Lowe N J. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001; 323 596-599
- 59 Heckmann M, Ceballos-Baumann A O, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med. 2001; 344 488-493
- 60 Lipp A, Trottenberg T, Schink T et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003; 61 1279-1281
- 61 Aurora S K, Dodick D W, Turkel CC et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30 793-803
- 62 Diener H C, Dodick D W, Aurora S K et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30 804-814
- 63 Blumenfeld A, Silberstein S D, Dodick D W et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010; 50 1406-1418
- 64 Dykstra D D, Sidi A A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990; 71 24-26
- 65 Seze de M, Petit H, Gallien P et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002; 42 56-62
Prof. Dr. med. Jörg Wissel
Neurologische Rehabilitationsklinik Beelitz-Heilstätten
Paracelsusring 6a
14547 Beelitz-Heilstätten
eMail: joerg@schwarz-wissel.de